| Literature DB >> 34946708 |
Wioletta Jakubczak1, Maja Haczyk-Więcek1, Katarzyna Pawlak1.
Abstract
In this study, we developed a strategy to determine atto- and femtomolar amounts of metal ions in lysates and mineralizates of cells (human non-small-cell lung carcinoma (NSCLC, A549) and normal lung (MRC-5)) exposed to cytotoxic metallo-drugs: cisplatin and auranofin at concentrations close to the half-maximal inhibitory drug concentrations (IC50). The developed strategy combines data obtained using biological and chemical approaches. Cell density was determined using two independent cell staining assays using trypan blue, calcein AM/propidium iodide. Metal concentrations in lysed and mineralized cells were established employing a mass spectrometer with inductively coupled plasma (ICP-MS) and equipped with a cross-flow nebulizer working in aspiration mode. It allowed for detecting of less than 1 fg of metal per cell. To decrease the required amount of sample material (from 1.5 mL to ~100 µL) without loss of sensitivity, the sample was introduced as a narrow band into a constant stream of liquid (flow-injection analysis). It was noticed that the selectivity of cisplatin accumulation by cells depends on the incubation time. This complex is accumulated by cells at a lower efficiency than auranofin and is found primarily in the lysate representing the cytosol. In contrast, auranofin interacts with water-insoluble compounds. Despite their different mechanism of action, both metallo-drugs increased the accumulation of transition metal ions responsible for oxidative stress.Entities:
Keywords: ICP-MS; auranofin; cisplatin; cytotoxicity; gold; lung cancer; metal determination; platinum
Mesh:
Substances:
Year: 2021 PMID: 34946708 PMCID: PMC8703441 DOI: 10.3390/molecules26247627
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Schematic presentation of the procedure established to study the accumulation of metallo-drugs and their effects on the metal homeostasis in lung cancer and normal cells by ICP-MS.
Figure 2Metallodrugs (auranofin and cisplatin) concentration required for 50% inhibition of cell biochemical function (IC50) determined for A-549 cancer cells and normal MRC-5 cells after different incubation times and correlation coefficient (r2). IC50 was established using automatically fitted curves described by Hill equation to relative changes of absorbance obtained via MTT test (Dr Fit software) for cancer lung cells A549 and normal lung cells MRC-5 exposed to auranofin and cisplatin for 72 h (a). Microscopic images were obtained for lung cancer (A549) and normal (MRC-5) cells exposed to auranofin and cisplatin stained with calcein (CAM, green), propidium iodide (PI, red), and trypan blue (grey) (b).
Figure 3(a) The effectiveness of the sample introduction system rinsing with 2% hydrochloric acid solution after the introduction of gold (10 ng/mL) standard solution. VGN—V-groove nebulizer, CCN—concentric nebulizer, CFN—cross-flow nebulizer. (b) Changes of the signal intensity for 197Au during FIA injections of 0.5 and 1.0 ng/mL Au in a solution of lysate diluted in proportion 1:3 equal to 17 and 34 fg of Au per cell. A 50 µL sample injected by Rheodyne valve into 0.5 mL/min mobile phase transported via PEEK tube with ID 0.13 mm.
Concentrations of Pt and Au in lysates established for different dilution ratios.
| Drug and Monitored Isotope | Drug Concentration in the Growth Medium [μM] | Concentration of Metal in Lysate [ng/mL] for Different Dilution Ratios ( | ||
|---|---|---|---|---|
| 1:1 | 1:3 | 1:5 | ||
| Cisplatin, 195Pt | 0.1 | 0.23 ± 0.10 | 0.08 ± 0.01 | 0.07 ± 0.04 |
| 25.0 | 12.0 ± 2.0 | 4.4 ± 0.1 | 4.2 ± 0.2 | |
| Auranofin, 197Au | 0.1 | 13.1 ± 1.1 | 6.0 ± 0.2 | 6.0 ± 0.2 |
| 1.4 | 115.0 ± 5.6 | 56.8 ± 0.7 | 55.2± 0.9 | |
Figure 4Calibration curve obtained for determination of Au, IISM (a) and transformation of calibration curve for determination of copper in cells’ lysate EISM→IISM (b). Detailed statistical characteristics of calibration curves for investigated metals is presented in Table S4.
Amounts of gold and platinum established for cells’ mineralizate and lysate (water-soluble compounds).
| Cdrug [µM] | Total Amount of Metal [Fmole/Cell] (DBY) | Amount of Metal in Cells’ Lysate [Fmole/Cell] | ||
|---|---|---|---|---|
| MRC-5 | A-549 | MRC-5 | A-549 | |
| Cisplatin (Pt content) | ||||
| 0.1 | 0.36 ± 0.11 (3%) | 8.05 ± 0.70 (39%) | 0.297 ± 0.059 | 0.036 ± 0.006 |
| 6.0 | 2.46 ± 0.80 (<1%) | 14.87 ± 4.08 (<1%) | 1.631 ± 0.264 | 0.913± 0.224 |
| 10.0 | 5.95 ± 1.29 (<1%) | 35.80 ± 8.99 (<1%) | 4.590 ± 0.700 | 1.297 ± 0.308 |
| 25.0 | 32.31 ± 3.10 (<1%) | 49.33 ± 13.70 (<1%) | 3.713 ± 0.387 | 2.318 ± 0.967 |
| Auranofin (Au content) | ||||
| 0.1 | 3.35 ± 0.57 (33%) | 19.90 ± 2.26 (85%) | 0.020 ± 0.005 | 1.660 ± 0.304 |
| 0.6 | 13.30 ± 1.54 (10%) | 32.74 ± 5.43 (7%) | 1.081 ± 0.119 | 1.508 ± 0.287 |
| 1.0 | 21.83 ± 2.61 (10%) | 56.45 ± 14.95 (8%) | 2.320 ± 0.237 | 1.609 ± 0.462 |
| 1.4 | 39.44 ± 5.25 (2%) | 51.93 ± 12.70 (4%) | 2.254 ± 0.484 | 2.589 ± 0.655 |
LOD = 0.010 fmole of Pt/cell and 0.003 fmole of Au/cell.
Figure 5Heat-map showing changes of relative metal amounts in lysates of cells exposed to auranofin (a) and cisplatin (b) obtained with Morpheus software (https://software.broadinstitute.org/morpheus, accessed on 1 December 2021) [52]. Changes of Ca2+ (and other metals) amounts in cytosol and mitochondria established as the ratio of the fluorescence obtained for cells exposed to auranofin and cisplatin (FE) against fluorescence obtained for the control group (FC). *—p < 0.05.
Optimal parameters for metal determination by two ICP-MS instruments (HP7500 and HP7700).
| Parameter | HP7500 | HP7700 |
|---|---|---|
| Plasma power | 1310 W | 1500 W |
| Double charged | 0.1% | 0.2% |
| Nebulizer gas flow | 1.1 L/min | |
| Nebulizer | Cross-flow, CFN | Concentric, CCN |
| Sample/mobile phase flow | 0.4/0.5 mL/min | |
| Gas (He/H2) flow | N/A | 2 mL/min |
| Monitored isotopes | 55Mn, 57Fe, 60Ni, 63Cu, 66Zn, 95Mo, 195Pt, 197Au | [He]: 23Na, 24Mg, 39K, 55Mn, 57Fe, 60Ni, 63Cu, 66Zn, 78Se, 195Pt, 197Au |
| Monitored ratios for isotopes for correction of interferences: [75/77 and 77/82] for Mn, Ni, and Cu; [195/177] for Pt; [197/181] for Au | ||
| Internal standards | 89Y, 103Rh | |
| Integration time | 0.1 s | |
[He]—metals determined using helium as collision gas, [H2]—metals determined using hydrogen as a reaction gas.